Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer

Experimental and Molecular Pathology

Volumn 66, Issue 2, 1999, Pages 170-178

  Mark, Hon Fong L ^a   Feldman, David ^a   Das, Sam ^a   Kye, Hyunseung ^a   Mark, Seamus ^a   Sun, Ci Lin ^a   Samy, Mangala ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

FISH; Fluorescent in situ hybridization; HER 2 neu; Oncogene amplification; Prostate cancer

Indexed keywords

TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CHROMOSOME 17; CONTROLLED STUDY; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

EID: 0032806848     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1006/exmp.1999.2242     Document Type: Article

References (31)

1. Afify A., Bland K. I., Mark H. F. L. Fluorescent in situ hybridization assessment of chromosome 8 copy number in breast cancer. Breast Cancer Res. Treatment. 38:1996;201-208.
2. Afify A., Mark H. F. L. FISH assessment of chromosome 8 copy number in Stage I and Stage II infiltrating ductal carcinoma of the breast. Cancer Genet. Cytogenet. 97:1997;101-105.
3. Allred D. C., Clark G. M., Tandon A. K., Molina R., Tormey D. C., Osborne C. K., Gilchrist K. W., Mansour E. G., Abeloff M., Eudey L., McGuire W. L. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 10:1992;599-605.
4. Bacus S. S., Zelmek C. R., Plowman G., Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am. J. Clin. Pathol. 102:1994;S13-S24.
5. Bangma C. H., Kranse R., Blijenberg B. G., Schroeder F. H. The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1726 men. Urology. 46:1995;773-778.
6. Bland K. I. The molecular pathology of colorectal and mammary carcinoma: Prognostic and therapeutic implications for surgeons. Ann. Surg. 222:1995;II-VII.
7. Bland K. I., Konstadoulaki M. M., Vezeridis M. P., Wanebo H. J. Oncogene protein co-expression: Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann. Surg. 221:1995;706-720.
8. Carter H. B., Partin A. W. Diagnosis and staging of prostate cancer. Walsh P. C. Campbell's Urology. 1998;7th ed. Saunders, Philadelphia.
9. Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N. Engl. J. Med. 320:1989;627-633.
10. Costa M. J., Walls J., Trelford J. D. C-erb B-2 oncogene overexpression in uterine cervix carcinoma with glandular differentiation. Am. J. Clin. Pathol. 204:1995;634-642.
11. De Potter C. R. The neu-oncogene: More than a prognostic indicator. Hum. Pathol. 25:1994;1264-1268.
12. Fournier G., Latil A., Amet Y., Abalain J. H., Volant A., Mangin P., Floch H. H., Lidereau R. Gene amplification in advanced-stage human prostate cancer. Urol. Res. 22:1995;343-347.
13. Grignon D. J., Hammond E. H. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the prostate cancer working group. Arch. Pathol. Lab. Med. 119:1995;1122-1126.
14. Gullick W. J., Love S. B., Wright C., Barnes D. M., Gusterson B., Harris A. L., Altman D. G. C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer. 63:1991;434-438.
15. Hedley D. W., Freidlander M., Taylor I., Rugg C., Musgrove E. Method for analysis of cellular DNA content of paraffin embedded pathological material using flow cytometry. J. Histochem. Cytochem. 31:1983;1331-1335.
16. Kuhn E. J., Kurnot R. A., Sesterhenn I. A., Chang E. H., Moul J. W. Expression of the c-erb B-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol. 150:1993;1427-1433.
17. Mark H. F. L. Fluorescent in situ hybridization as an adjunct to conventional cytogenetics. Ann. Clin. Lab. Sci. 24:1994;153-163.
18. Mark H. F. L., Afify A., Taylor W., Santoro K., Lathrop J. A subset of gestational trophoblastic disease characterized by abnormal chromosome 8 copy number detected by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 99:1997a;24-29.
19. Mark H. F. L., Aswad B., Bassily N., Taylor W., Brown S., Sun C.-L., Samy M., Zolnierz K., Wong E., Kim D., Bland K. I., Hsu P. H. HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization. Genet. Med. 1999.
20. Mark H. F. L., Brown S., Samy M., Sun C.-L., Santoro K., Afify A. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology. 66:1998;59-63.
21. Mark H. F. L., Huth A., Santoro K., Ferreira K., Barker B. Sequential flow cytometry and FISH for the study of formalin-fixed paraffin-embedded breast cancer tissues. Cancer Genet. Cytogenet. 98:1997b;1-5.
22. Persons D. L., Borelli K. A., Hsu P. H. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod. Pathol. 10:1997;720-727.
23. Press M. F., Hung G., Godolphin W., Slamon D. J. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies on oncogene expression. Cancer Res. 54:1994;2771-2776.
24. Press M. F., Pike M. C, Chanzin V. R., Hung G., Udove J. A., Markowicz M., Danyluk J., Godolphin W., Sliwkowski M., Akita R., Paterson M. C., Slamon D. J. HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with in creased risk of recurrent disease. Cancer Res. 53:1993;4960-4970.
25. Ross J. S., Nazeer T., Church K., Amato C., Figge H., Rifkin M. D., Fisher H. A. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer. 72:1993;3020-3028.
26. Sadasivan R., Morgan R., Jennings S., Austenfeld M., Veldhuizen P. V., Stephens R., Noble M. Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol. 150:1993;126-131.
27. Sandberg, A. A. (1990). "The Chromosomes in Human Cancer and Leukemia." Elsevier, New York.
28. Shi X. B., Gumerlock P. H., deVere-White R. W. Molecular biology of prostate cancer. World J. Urol. 14:1996;318-328.
29. Slamon D. J. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
30. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
31. Zhau H. Z., Wan D. S., Jhou J. X., Miller G. J., Eschenbach A. C. V. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissue and cell lines. Mol. Carinog. 5:1992;320-327.